Research Article
Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
Table 5
Clinical characteristics at baseline and change after 24 weeks.
| | Characteristics | At baseline, | After 24 weeks, | value |
| | Body mass (kg) | | | <0.001 | | BMI (kg/m2) | | | <0.001 | | WC (cm) | | | <0.001 | | НbA1c (%) | | | <0.001 | | Glucose fasting (mmol/l) | | | 0.004 | | SBP (mm Hg) | | | 0.001 | | DBP (mm Hg) | | | 0.001 | | TC (mmol/l) | | | 0.215 | | HDL (mmol/l) | 1.0 (0.8; 1.3) | 1.1 (0.9; 1.3) | 0.565 | | LDL (mmol/l) | | | 0.189 | | TG (mmol/l) | 1.9 (1.5; 3.2) | 1.7 (1.4; 3.1) | 0.076 | | C-peptide fasting (ng/ml) | | | 0.569 | | C-peptide after test (ng/ml) | | | 0.066 | | НОМА-IR | | | 0.089 | | НОМА-β | 35.7 (24.5; 61.0) | 35.3 (27.3; 57.3) | 0.716 |
|
|
2 hours after breakfast in meal tolerance test. |
